NHS England becomes world's first healthcare system to offer "Trojan horse" cancer therapy that triples remission time for blood cancer patients.

Tejal Somvanshi

How does this treatment work? The therapy sneaks powerful cancer-killing drugs directly into cancer cells, destroying them from within.

Photo Source: Free Range Stock(CC0)

Clinical trials revealed stunning results: 71% of patients remained progression-free after one year, compared to just 51% with standard treatments.

Photo Source: RDNE Stock project (Pexels)

For the 1,500 myeloma patients in England who will receive this treatment annually, the therapy keeps cancer at bay for 3 years versus just 13 months with current methods.

Photo Source: ZEISS Microscopy (CC BY-NC-ND 2.0)

Paul Silvester, 60, experienced remission within weeks after starting the treatment: "It brought the party balloons back in the house."

Photo Source: Tima Miroshnichenko (Pexels)

The treatment combines belantamab mafodotin (given as a 30-minute infusion) with two other medications to target multiple myeloma, an incurable bone marrow cancer.

Photo Source: Samlevin (CC BY 2.0)

Unlike traditional treatments that can require months of isolation, patients can maintain normal lives – Paul is now planning trips to historical sites and his daughter's graduation.

Photo Source: Pexels (CC0)

Side effects are notably milder than standard treatments, though some patients may experience dry eyes and blurred vision that can be managed with regular monitoring.

Photo Source: Cottonbro Studio (Pexels)

Professor Martin Kaiser from the Institute of Cancer Research calls these "very smart drugs" and predicts long-term remission rates will exceed 50% in five years.

Photo Source: Los Muertos Crew (Pexels)

Developed in the UK, this therapy represents a major step toward what experts call "a functional cure" for a previously incurable cancer.

Photo Credit: Darryl Leja (PDM 1.0)

Next Story

NHS Psychological Support Opens for Blood Scandal Victims